Home / Deep Research / Craniopharyngioma

Craniopharyngioma

Subtype summary table (evidence-linked)

2026-05-11
Falcon MONDO:0018907 Model: Edison Scientific Literature 48 citations

1. Disease Information

1.1 Overview / definition (current understanding)

Craniopharyngiomas are rare epithelial intracranial neoplasms that arise along the craniopharyngeal duct / from remnants of Rathke’s pouch, typically in the sellar and suprasellar region, often extending toward the third ventricle (neto2025recentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 1-2, campanini2023themolecularpathogenesis pages 2-3). Their clinical impact is largely due to proximity to the optic apparatus, pituitary gland, and hypothalamus, causing visual and endocrine morbidity (biswas2024practicalapplicationof pages 1-2, brastianos2023brafmekinhibitionin pages 1-4).

The WHO classifies craniopharyngiomas as histologically benign WHO grade 1 tumors, but they can behave aggressively via adherence/invasion of adjacent critical structures (campanini2023themolecularpathogenesis pages 1-2, neto2025recentadvancesin pages 1-2).

1.2 Key synonyms / alternative names

Commonly used names include adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP), which the 2021 WHO CNS classification treats as separate tumor entities (biswas2024practicalapplicationof pages 1-2, jannelli2023currentadvancesin pages 1-2).

1.3 Source type note

Most information in this report is derived from aggregated disease-level resources (systematic reviews, narrative reviews, population registries) and clinical trials; some mechanistic claims are supported by primary molecular studies using human tissue and model systems (brastianos2023brafmekinhibitionin pages 1-4, apps2018tumourcompartmenttranscriptomics pages 1-2, wang2024multiomicsanalysisof pages 1-2).

2. Etiology

2.1 Disease causal factors

Primary causal factors are molecular drivers that define two biologically distinct entities: - Adamantinomatous craniopharyngioma (ACP): driven by somatic CTNNB1 mutations (β‑catenin), with Wnt/β‑catenin pathway activation and β‑catenin accumulation in characteristic cell clusters (campanini2023themolecularpathogenesis pages 1-2, campanini2023themolecularpathogenesis pages 4-6). - Papillary craniopharyngioma (PCP): driven by BRAF p.(V600E) in ~90–95% (or higher) of cases, activating MAPK/ERK signaling (jannelli2023currentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 1-2, campanini2023themolecularpathogenesis pages 2-3).

2.2 Risk factors

No clear environmental or lifestyle risk factors were identified in the retrieved evidence; CPs are generally considered sporadic tumors with age‑related incidence peaks (an2025molecularsubtypesof pages 1-2, javidialsaadi2025advancesinthe pages 2-4).

2.3 Protective factors / gene–environment interactions

No protective factors or gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes (clinical presentation)

3.1 Common symptoms and signs (with frequencies where available)

Craniopharyngiomas typically have insidious onset with symptoms driven by mass effect and hypothalamic–pituitary involvement (javidialsaadi2025advancesinthe pages 4-6, alboqami2024craniopharyngiomaacomprehensive pages 2-5).

Frequent manifestations include: - Headache: reported as 83.6% in one synthesis, and commonly 50–80% across reviews (javidialsaadi2025advancesinthe pages 4-6, gonzalezgallego2025moderntreatmentof pages 2-4). - Visual deficits: reported as 81.6% in one synthesis; classic bitemporal hemianopia due to optic chiasm compression, and decreased visual acuity (javidialsaadi2025advancesinthe pages 4-6, alboqami2024craniopharyngiomaacomprehensive pages 2-5, gonzalezgallego2025moderntreatmentof pages 2-4). - Endocrine dysfunction (pituitary axis deficits): endocrine deficits are common (e.g., 75–90% in one review synthesis), including central hypothyroidism, hypogonadism, adrenal insufficiency, and diabetes insipidus (gonzalezgallego2025moderntreatmentof pages 2-4, alboqami2024craniopharyngiomaacomprehensive pages 2-5). - Hydrocephalus / raised intracranial pressure: obstruction of the third ventricle can cause hydrocephalus; reported ranges include 10–30% for obstructive hydrocephalus in one synthesis (alboqami2024craniopharyngiomaacomprehensive pages 2-5, gonzalezgallego2025moderntreatmentof pages 2-4).

Additional phenotype frequencies reported in one review synthesis include endocrine deficit subtypes such as growth hormone deficiency (~85%), gonadotroph deficiency (~40%), ACTH (~25%), TSH (~25%), and diabetes insipidus (~20%) (javidialsaadi2025advancesinthe pages 6-8).

3.2 Quality-of-life impact

High overall survival contrasts with long‑term morbidity, driven by visual loss, neuroendocrine deficits, and hypothalamic dysfunction (brastianos2023brafmekinhibitionin pages 1-4, biswas2024practicalapplicationof pages 1-2).

3.3 Suggested HPO terms (examples)

(HPO identifiers are provided as ontology suggestions; specific term mapping may be refined for local database standards.)

4. Genetic / Molecular Information

4.1 Causal genes and hallmark alterations

4.2 Molecular subgroups (recent development: 2024 multi‑omics)

A 2024 multi‑omics study profiled a large cohort (119 ACP and 23 PCP among 142 cases) using WES/RNA‑seq/DNA methylation and defined three ACP molecular subgroups—WNT, ImA, and ImB—with distinct pathway activation and imaging/histologic correlates (wang2024multiomicsanalysisof pages 1-2). The WNT subgroup showed stronger Wnt/β‑catenin activity and more epithelial/solid tumors, whereas ImA/ImB showed inflammatory and interferon responses with more cystic tumors and immune infiltration (wang2024multiomicsanalysisof pages 1-2). Prognostically, WNT had better event‑free survival than ImB, and ImA/ImB were predicted more likely to respond to immune checkpoint blockade than WNT (wang2024multiomicsanalysisof pages 1-2, wang2024multiomicsanalysisof pages 8-10).

4.3 Inflammation and tumor microenvironment

Mechanistic tissue studies support that ACP contains a prominent inflammatory microenvironment; tumor clusters are surrounded by gliosis/inflammatory reaction, and inflammatory programs (including inflammasome activation) have been described in transcriptomic/proteomic studies (campanini2023themolecularpathogenesis pages 4-6, apps2018tumourcompartmenttranscriptomics pages 1-2).

4.4 Suggested GO biological process terms (examples)

5. Environmental Information

No specific environmental, lifestyle, or infectious causal agents were identified in the retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Subtype-specific upstream drivers → downstream disease features (causal chains)

ACP causal chain (simplified): Somatic CTNNB1 mutation → stabilization/nuclear accumulation of β‑catenin in discrete tumor clusters → Wnt/β‑catenin hyperactivation with cluster cells acting as signaling centers → secretion of growth factors/cytokines/chemokines and remodeling of surrounding tissue with gliosis/inflammation → locally invasive behavior with cyst formation and adherence to hypothalamus/optic pathways → clinical syndrome of visual deficits and endocrine/hypothalamic dysfunction (campanini2023themolecularpathogenesis pages 4-6, apps2018tumourcompartmenttranscriptomics pages 1-2, alboqami2024craniopharyngiomaacomprehensive pages 2-5).

PCP causal chain (simplified): BRAF p.(V600E) mutation → MAPK/ERK pathway activation → growth of predominantly solid suprasellar tumor mass → optic chiasm compression and pituitary stalk/gland dysfunction → visual field loss and hypopituitarism; importantly, the dominant oncogenic driver yields high sensitivity to BRAF/MEK inhibitors (campanini2023themolecularpathogenesis pages 2-3, brastianos2023brafmekinhibitionin pages 1-4).

6.2 MAPK/ERK activity in ACP and therapeutic implications

Although ACP is classically Wnt‑driven, MAPK/ERK pathway activation has been observed in compartments of ACP, and MEK inhibition with trametinib in ex vivo ACP tissue reduced pERK1/2, increased apoptosis, and decreased proliferation (campanini2023themolecularpathogenesis pages 4-6). This provides biological rationale for MEK‑inhibitor trials in ACP (NCT05286788 chunk 1).

6.3 Advanced technologies (recent)

  • Single-cell and spatial sequencing have been applied to ACP (70,682 cells profiled in one 2024 study) to refine tumor-cell states including senescence‑associated secretory phenotype (SASP) programs and immune infiltration ().
  • Multi‑omics clustering (WES/RNA‑seq/DNAm) is being used to derive prognostic and predicted treatment-response subgroups (wang2024multiomicsanalysisof pages 1-2).

6.4 Suggested Cell Ontology (CL) terms (examples)

  • Pituitary stem/progenitor cell (for mechanistic models): CL:0002371 (pituitary gland stem cell; exact label may vary by ontology version)
  • T cell: CL:0000084
  • Macrophage / microglia: CL:0000235 (macrophage), CL:0000129 (microglial cell)
  • Astrocyte (astrogliosis): CL:0000127

7. Anatomical Structures Affected

7.1 Primary sites

Craniopharyngiomas arise in the sellar/suprasellar region, near the pituitary–hypothalamic axis (campanini2023themolecularpathogenesis pages 1-2, brastianos2023brafmekinhibitionin pages 1-4).

7.2 Secondary structures commonly involved (by local extension)

Commonly impacted structures include the optic chiasm/optic apparatus, pituitary stalk, hypothalamus, and sometimes the third ventricle (alboqami2024craniopharyngiomaacomprehensive pages 2-5, campanini2023themolecularpathogenesis pages 2-3).

7.3 Suggested UBERON terms (examples)

8. Temporal Development

8.1 Onset

Craniopharyngiomas show a bimodal age distribution with a pediatric peak (~5–14/15 years) and an adult peak (variously reported ~45–60 or ~50–74 years) (an2025molecularsubtypesof pages 1-2, javidialsaadi2025advancesinthe pages 2-4, neto2025recentadvancesin pages 1-2).

8.2 Progression/course

They are slow-growing but often chronic due to recurrence and long-term morbidity after treatment in this anatomically constrained region (brastianos2023brafmekinhibitionin pages 1-4, neto2025recentadvancesin pages 1-2).

9. Inheritance and Population

9.1 Epidemiology (key statistics)

9.2 Sex ratio / demographics

Some reviews report no gender predilection overall (neto2025recentadvancesin pages 1-2). Subtype distribution is age-skewed: ACP occurs in both children and adults; PCP is largely adult (neto2025recentadvancesin pages 1-2, jannelli2023currentadvancesin pages 1-2).

10. Diagnostics

10.1 Imaging

Diagnosis is suggested by a sellar/suprasellar mass with cystic and/or solid components on MRI/CT; CT is particularly useful for calcifications, while MRI delineates soft tissue, cystic components, and relationships to the optic chiasm, pituitary stalk/gland, and hypothalamus (gonzalezgallego2025moderntreatmentof pages 2-4, javidialsaadi2025advancesinthe pages 6-8).

Calcifications are emphasized as frequent (reported ~90% in one review synthesis) (alboqami2024craniopharyngiomaacomprehensive pages 2-5).

10.2 Histopathology (ACP vs PCP)

10.3 Molecular testing

Molecular testing is clinically actionable in PCP: identifying BRAF V600E enables use of BRAF/MEK inhibition (brastianos2023brafmekinhibitionin pages 1-4, NCT05525273 chunk 1).

10.4 Differential diagnosis

Differential diagnosis is not comprehensively extracted from the available evidence snippets in this run; however, in practice it typically includes other sellar/suprasellar masses (e.g., pituitary adenomas, Rathke cleft cyst, germ cell tumors). A dedicated diagnostic radiology/pathology source would be needed for a fully cited differential list.

11. Outcome / Prognosis

11.1 Survival

Overall survival is generally favorable compared with malignant brain tumors, but long-term morbidity is high due to location and treatment effects (brastianos2023brafmekinhibitionin pages 1-4, biswas2024practicalapplicationof pages 1-2). A narrative review reports wide 10‑year survival ranges (40–95%) reflecting heterogeneity and treatment era differences (javidialsaadi2025advancesinthe pages 4-6).

11.2 Morbidity and quality-of-life outcomes

Major long-term morbidities include persistent endocrine deficits and hypothalamic dysfunction; hypothalamic injury is a key driver of severe sequelae (gonzalezgallego2025moderntreatmentof pages 2-4, brastianos2023brafmekinhibitionin pages 1-4).

12. Treatment

12.1 Surgery and radiotherapy (standard-of-care backbone)

Standard management historically relies on maximal safe resection with adjuvant radiotherapy when necessary, balanced against risk of hypothalamic/optic injury (brastianos2023brafmekinhibitionin pages 1-4, biswas2024practicalapplicationof pages 1-2).

12.2 Targeted therapy — major 2023–2024 development (PCP)

A pivotal 2023 phase II study (papillary CP, BRAF‑mutant, no prior radiation) treated 16 patients with vemurafenib + cobimetinib and reported: 15/16 (94%) durable partial response or better, median tumor volume reduction 91%, and 12‑month PFS 87% (24‑month PFS 58%) (brastianos2023brafmekinhibitionin pages 1-4).

Direct abstract quotes supporting this include: - “Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations” (Brastianos et al., 2023) (brastianos2023brafmekinhibitionin pages 1-4). - “15 (94% …) had a durable objective partial response or better… The median reduction in the volume of the tumor was 91%” (brastianos2023brafmekinhibitionin pages 1-4).

A 2024 systematic review summarizing neoadjuvant/adjuvant BRAF±MEK inhibitor use in PCP found volumetric reductions ranging 24–100%, with ≥80% reductions reported in 64% of adjuvant cases, and near‑complete responses common in neoadjuvant settings (cossu2024updateonneoadjuvant pages 1-2).

Real-world implementation pattern: targeted therapy is increasingly used to de‑escalate morbid surgery/radiation in BRAF‑mutant PCP, while emphasizing multidisciplinary planning and close toxicity monitoring (biswas2024practicalapplicationof pages 2-3, NCT05525273 chunk 1).

12.3 MEK inhibition / inflammatory targeting — emerging for ACP

  • A phase 2 clinical trial is evaluating binimetinib (MEKTOVI®) in pediatric/young adult ACP (NCT05286788) (NCT05286788 chunk 1).
  • Preclinical evidence supports MEK/MAPK pathway involvement in subsets of ACP and sensitivity to MEK inhibition ex vivo (campanini2023themolecularpathogenesis pages 4-6).

12.4 Intracystic therapy (cystic CP)

A 2024 retrospective case series evaluated intracystic peginterferon alfa‑2a delivered weekly ×6 via Ommaya reservoir in 5 patients with cystic CP, reporting cyst shrinkage in all five and good tolerability ().

12.5 Brachytherapy for cystic CP (meta-analysis)

A 2024 systematic review/meta-analysis of brachytherapy in cystic CP (6 trials, 266 patients; ≥5-year follow-up) reported pooled PFS: 75% at 1 year, 62% at 2–3 years, and 57% at 5 years (zhang2024brachytherapyincraniopharyngiomas pages 1-2).

12.6 Suggested MAXO terms (examples)

  • Surgical resection: MAXO:0001041 (surgical procedure; refine locally)
  • Radiotherapy: MAXO:0000558
  • Targeted molecular therapy (BRAF/MEK inhibitors): MAXO:0001035 (drug therapy; refine)
  • Intracystic therapy via reservoir: MAXO:0001176 (intrathecal/intralesional administration; refine)

(MAXO identifiers are provided as ontology suggestions; mapping may require local curation.)

13. Prevention

No established primary prevention strategies exist because CPs are not linked to modifiable exposures in the retrieved evidence. Secondary/tertiary “prevention” in practice centers on early diagnosis and hypothalamus/optic-sparing treatment strategies to reduce long-term morbidity (brastianos2023brafmekinhibitionin pages 1-4).

14. Other Species / Natural Disease

No naturally occurring non-human species disease evidence was retrieved in this run.

15. Model Organisms / Experimental Models

15.1 Genetically engineered mouse models (ACP)

Mouse genetic models targeting oncogenic β‑catenin to pituitary embryonic precursors or adult stem cells have been used to model ACP tumorigenesis and support a paracrine mechanism in which cluster cells act as signaling centers (apps2017geneticallyengineeredmouse pages 3-5, apps2018tumourcompartmenttranscriptomics pages 1-2).

15.2 Ex vivo explant models and translational testing

Human and mouse ACP explant cultures treated with the MEK inhibitor trametinib showed reduced proliferation and increased apoptosis, providing a preclinical platform for therapy development (apps2018tumourcompartmenttranscriptomics pages 1-2, campanini2023themolecularpathogenesis pages 4-6).

15.3 Suggested resources

Open pediatric cancer multi‑omics initiatives (e.g., OpenPBTA/OpenPedCan) are expanding integrated diagnoses and methylation-based subtyping for pediatric brain tumors including craniopharyngioma ().

Subtype summary table (evidence-linked)

Table (click to expand)
Subtype Relative frequency Key driver mutation(s) Typical age distribution Imaging / histopathology Therapy implications
Adamantinomatous craniopharyngioma (ACP) ~90% of craniopharyngiomas (jannelli2023currentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 2-3, campanini2023themolecularpathogenesis pages 1-2) Somatic CTNNB1 exon 3 mutation; reported prevalence ranges include ~60%, 59%, and ~69-100% across studies/reviews; causes nuclear/cytoplasmic β-catenin accumulation and Wnt/β-catenin activation (an2025molecularsubtypesof pages 1-2, neubecker2026systemicmolecularlytargeted pages 1-2, campanini2023themolecularpathogenesis pages 1-2, wang2024multiomicsanalysisof pages 3-5) Bimodal peaks in childhood and later adulthood: 5-15 years and 45-60 years; other reviews report 5-14 and 55-74 years (an2025molecularsubtypesof pages 1-2, neto2025recentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 2-3, javidialsaadi2025advancesinthe pages 2-4) Often multicystic or mixed solid-cystic; calcifications common (~90%); CT often shows hypodense cystic uni-/multilocular lesion; cyst fluid may resemble “motor oil.” Histology: palisading epithelium, stellate reticulum, finger-like infiltrative protrusions, wet keratin, epithelial whorls, gliosis/inflammation (alboqami2024craniopharyngiomaacomprehensive pages 2-5, javidialsaadi2025advancesinthe pages 6-8, gonzalezgallego2025moderntreatmentof pages 2-4, campanini2023themolecularpathogenesis pages 4-6) Standard management remains maximal safe surgery ± radiotherapy. No single established targeted therapy yet. Emerging/experimental strategies include MEK inhibition (especially inflammatory/ImA subtype), IL-6/IL-6R blockade (e.g., tocilizumab), bevacizumab combinations, immunotherapy for inflammatory subgroups, and intracystic interferon/peginterferon for cystic disease (wang2024multiomicsanalysisof pages 8-10, wang2024multiomicsanalysisof pages 1-2, NCT05286788 chunk 1, wang2024multiomicsanalysisof pages 3-5)
Papillary craniopharyngioma (PCP) ~10% of craniopharyngiomas (jannelli2023currentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 2-3) BRAF p.V600E in ~90-95% of cases; reviews also report 81-100% or near-universal prevalence; activates MAPK/ERK signaling (jannelli2023currentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 2-3, campanini2023themolecularpathogenesis pages 1-2, NCT05525273 chunk 1) Predominantly adult-onset; typically 4th-6th decade / 40-53 years, mean ~44.7 years; often 5th-6th decades (neto2025recentadvancesin pages 1-2, jannelli2023currentadvancesin pages 1-2, campanini2023themolecularpathogenesis pages 2-3, NCT05525273 chunk 1) Typically solid or uniloculated, non-calcified suprasellar/tuberoinfundibular mass; CT/MRI often isodense and noncalcified with hyperintense T2 signal. Histology: mature squamous epithelium over fibrovascular cores; lacks ACP palisading, stellate reticulum, and wet keratin (alboqami2024craniopharyngiomaacomprehensive pages 2-5, javidialsaadi2025advancesinthe pages 6-8, gonzalezgallego2025moderntreatmentof pages 2-4) Strong precision-oncology signal: BRAF/MEK inhibition produces major shrinkage. In prospective phase 2 data, 15/16 (94%) responded, median tumor-volume reduction 91%, 12-month PFS 87%, 24-month PFS 58% with vemurafenib+cobimetinib; neoadjuvant/adjuvant regimens often allow less morbid surgery/radiation and in some cases no further therapy (brastianos2023brafmekinhibitionin pages 1-4, cossu2024updateonneoadjuvant pages 1-2, NCT03224767 chunk 1, NCT05525273 chunk 1)

Table: This table compares adamantinomatous and papillary craniopharyngioma across frequency, molecular drivers, age distribution, imaging and histopathologic features, and current therapeutic implications. It is useful for quickly linking subtype biology to diagnostic expectations and treatment strategy.

Key Clinical Trials (selected)

  • NCT03224767 (Alliance A071601) — Adults (≥18) with BRAF V600E papillary CP; vemurafenib + cobimetinib; phase II; primary endpoint objective response at 4 months; includes two cohorts (no prior RT vs prior RT) (NCT03224767 chunk 1). This trial is the basis for the NEJM 2023 phase II results summarized above (brastianos2023brafmekinhibitionin pages 1-4).
  • NCT05525273 (Swecranio) — Adults with BRAF V600E papillary CP; dabrafenib + trametinib; phase II; primary endpoint maximal tumor-volume reduction on MRI and QoL/visual/endocrine outcomes as secondary endpoints (NCT05525273 chunk 1).
  • NCT05286788 (CONNECT2108) — Pediatric/young adult ACP; binimetinib; phase II; objective response endpoints stratified by prior radiation (NCT05286788 chunk 1).

ClinicalTrials.gov URLs: - NCT03224767: https://clinicaltrials.gov/study/NCT03224767 (NCT03224767 chunk 1) - NCT05525273: https://clinicaltrials.gov/study/NCT05525273 (NCT05525273 chunk 1) - NCT05286788: https://clinicaltrials.gov/study/NCT05286788 (NCT05286788 chunk 1)

Notes on evidence gaps / limitations

1) Ontology identifier codes (MONDO, Orphanet, ICD-10/11, MeSH, OMIM) were not accessible through the current scholarly-literature and ClinicalTrials.gov toolchain and therefore are not included as authoritative code assertions in this report. 2) Some requested elements (detailed differential diagnosis list; population prevalence; long-term endocrine/visual outcome rates by treatment modality) require additional dedicated sources or full-text extraction beyond the available evidence snippets.

Reference list (URLs and publication dates)

The citations above already embed URLs and publication months/years in the evidence source metadata; key recent/high-authority sources include: - Brastianos PK et al. N Engl J Med. July 2023. DOI: https://doi.org/10.1056/NEJMoa2213329 (brastianos2023brafmekinhibitionin pages 1-4) - Alboqami MN et al. Heliyon. June 2024. DOI: https://doi.org/10.1016/j.heliyon.2024.e32112 (alboqami2024craniopharyngiomaacomprehensive pages 2-5) - Biswas C et al. Front Endocrinol. Nov 2024. DOI: https://doi.org/10.3389/fendo.2024.1488958 (biswas2024practicalapplicationof pages 1-2) - Cossu G et al. Cancers (Basel). Oct 2024. DOI: https://doi.org/10.3390/cancers16203479 (cossu2024updateonneoadjuvant pages 1-2) - Wang X et al. Chinese Medical Journal. Aug 2024. DOI: https://doi.org/10.1097/CM9.0000000000002774 (wang2024multiomicsanalysisof pages 1-2) - Campanini ML et al. Arch Endocrinol Metab. Feb 2023. DOI: https://doi.org/10.20945/2359-3997000000600 (campanini2023themolecularpathogenesis pages 1-2)

References

  1. (campanini2023themolecularpathogenesis pages 1-2): Marina Lanciotti Campanini, João Paulo Almeida, Clarissa Silva Martins, and Margaret de Castro. The molecular pathogenesis of craniopharyngiomas. Archives of Endocrinology and Metabolism, 67:266-275, Feb 2023. URL: https://doi.org/10.20945/2359-3997000000600, doi:10.20945/2359-3997000000600. This article has 13 citations.

  2. (jannelli2023currentadvancesin pages 1-2): Gianpaolo Jannelli, Francesco Calvanese, Luca Paun, Gerald Raverot, and Emmanuel Jouanneau. Current advances in papillary craniopharyngioma: state-of-the-art therapies and overview of the literature. Brain Sciences, 13:515, Mar 2023. URL: https://doi.org/10.3390/brainsci13030515, doi:10.3390/brainsci13030515. This article has 28 citations.

  3. (neto2025recentadvancesin pages 1-2): Clariano Pires de Oliveira Neto, Gilvan Cortês Nascimento, Sabrina da Silva Pereira Damianse, and Manuel dos Santos Faria. Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches. Frontiers in Endocrinology, May 2025. URL: https://doi.org/10.3389/fendo.2025.1562942, doi:10.3389/fendo.2025.1562942. This article has 2 citations.

  4. (neubecker2026systemicmolecularlytargeted pages 1-2): Joseph J. Neubecker, Daniel W. Griepp, Jeffrey P. Turnbull, Joshua Caskey, Shivum Desai, Adam Mansour, Rabia Ahmed, Andrew Beggs, Annie T. K. Griepp, Heather Heitkotter, Chad F. Claus, Boyd F. Richards, and Prashant S. Kelkar. Systemic molecularly targeted therapies for neoadjuvant and salvage craniopharyngioma: a contemporary narrative review. Biomedicines, 14:499, Feb 2026. URL: https://doi.org/10.3390/biomedicines14030499, doi:10.3390/biomedicines14030499. This article has 0 citations.

  5. (campanini2023themolecularpathogenesis pages 2-3): Marina Lanciotti Campanini, João Paulo Almeida, Clarissa Silva Martins, and Margaret de Castro. The molecular pathogenesis of craniopharyngiomas. Archives of Endocrinology and Metabolism, 67:266-275, Feb 2023. URL: https://doi.org/10.20945/2359-3997000000600, doi:10.20945/2359-3997000000600. This article has 13 citations.

  6. (biswas2024practicalapplicationof pages 1-2): Chandrima Biswas, Guilherme Mansur, Kyle C. Wu, Daniel M. Prevedello, and Luma Ghalib. Practical application of precision oncology in adult onset craniopharyngiomas. Frontiers in Endocrinology, Nov 2024. URL: https://doi.org/10.3389/fendo.2024.1488958, doi:10.3389/fendo.2024.1488958. This article has 4 citations.

  7. (brastianos2023brafmekinhibitionin pages 1-4): Priscilla K. Brastianos, Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Shervin Tabrizi, Brian Kabat, Julia Thierauf, Michael W. Ruff, Daniela A. Bota, David A. Reardon, Adam L. Cohen, Macarena I. De La Fuente, Glenn J. Lesser, Jian Campian, Pankaj K. Agarwalla, Priya Kumthekar, Bhupinder Mann, Shivangi Vora, Michael Knopp, A. John Iafrate, William T. Curry, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Fred G. Barker, and Evanthia Galanis. Braf-mek inhibition in newly diagnosed papillary craniopharyngiomas. The New England journal of medicine, 389 2:118-126, Jul 2023. URL: https://doi.org/10.1056/nejmoa2213329, doi:10.1056/nejmoa2213329. This article has 127 citations and is from a highest quality peer-reviewed journal.

  8. (apps2018tumourcompartmenttranscriptomics pages 1-2): John R. Apps, Gabriela Carreno, Jose Mario Gonzalez-Meljem, Scott Haston, Romain Guiho, Julie E. Cooper, Saba Manshaei, Nital Jani, Annett Hölsken, Benedetta Pettorini, Robert J. Beynon, Deborah M. Simpson, Helen C. Fraser, Ying Hong, Shirleen Hallang, Thomas J. Stone, Alex Virasami, Andrew M. Donson, David Jones, Kristian Aquilina, Helen Spoudeas, Abhijit R. Joshi, Richard Grundy, Lisa C. D. Storer, Márta Korbonits, David A. Hilton, Kyoko Tossell, Selvam Thavaraj, Mark A. Ungless, Jesus Gil, Rolf Buslei, Todd Hankinson, Darren Hargrave, Colin Goding, Cynthia L. Andoniadou, Paul Brogan, Thomas S. Jacques, Hywel J. Williams, and Juan Pedro Martinez-Barbera. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the mapk/erk pathway as a novel therapeutic target. Acta Neuropathologica, 135:757-777, Mar 2018. URL: https://doi.org/10.1007/s00401-018-1830-2, doi:10.1007/s00401-018-1830-2. This article has 169 citations and is from a highest quality peer-reviewed journal.

  9. (wang2024multiomicsanalysisof pages 1-2): Xianlong Wang, Chuan Zhao, Jincheng Lin, Hongxing Liu, Qiuhong Zeng, Hua-Qing Chen, Ye Wang, Dapeng Xu, Wen Chen, Moping Xu, En Zhang, Da Lin, and Zhixiong Lin. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chinese Medical Journal, 137:859-870, Aug 2024. URL: https://doi.org/10.1097/cm9.0000000000002774, doi:10.1097/cm9.0000000000002774. This article has 21 citations and is from a peer-reviewed journal.

  10. (campanini2023themolecularpathogenesis pages 4-6): Marina Lanciotti Campanini, João Paulo Almeida, Clarissa Silva Martins, and Margaret de Castro. The molecular pathogenesis of craniopharyngiomas. Archives of Endocrinology and Metabolism, 67:266-275, Feb 2023. URL: https://doi.org/10.20945/2359-3997000000600, doi:10.20945/2359-3997000000600. This article has 13 citations.

  11. (an2025molecularsubtypesof pages 1-2): Wenhao An, Shouwei Li, Yihua An, and Zhixiong Lin. Molecular subtypes of adamantinomatous craniopharyngiomas. Neuro-Oncology, 27:1180-1192, Feb 2025. URL: https://doi.org/10.1093/neuonc/noaf030, doi:10.1093/neuonc/noaf030. This article has 9 citations and is from a domain leading peer-reviewed journal.

  12. (javidialsaadi2025advancesinthe pages 2-4): Mousa Javidialsaadi, Diego D. Luy, Heather L. Smith, Arba Cecia, Seunghyuk Daniel Yang, and Anand V. Germanwala. Advances in the management of craniopharyngioma: a narrative review of recent developments and clinical strategies. Journal of Clinical Medicine, 14:1101, Feb 2025. URL: https://doi.org/10.3390/jcm14041101, doi:10.3390/jcm14041101. This article has 7 citations.

  13. (javidialsaadi2025advancesinthe pages 4-6): Mousa Javidialsaadi, Diego D. Luy, Heather L. Smith, Arba Cecia, Seunghyuk Daniel Yang, and Anand V. Germanwala. Advances in the management of craniopharyngioma: a narrative review of recent developments and clinical strategies. Journal of Clinical Medicine, 14:1101, Feb 2025. URL: https://doi.org/10.3390/jcm14041101, doi:10.3390/jcm14041101. This article has 7 citations.

  14. (alboqami2024craniopharyngiomaacomprehensive pages 2-5): Maryam Nashi Alboqami, Arwa Khalid S Albaiahy, Bushra Hatim Bukhari, Ali Alkhaibary, Ahoud Alharbi, Sami Khairy, Ali H. Alassiri, Fahd AlSufiani, Ahmed Alkhani, and Ahmed Aloraidi. Craniopharyngioma: a comprehensive review of the clinical presentation, radiological findings, management, and future perspective. Heliyon, 10:e32112, Jun 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e32112, doi:10.1016/j.heliyon.2024.e32112. This article has 33 citations.

  15. (gonzalezgallego2025moderntreatmentof pages 2-4): Carlos González-Gallego, Pedro Molina, Cristina Hostalot, Anna Oliva, Alberto Blanco, Paloma Puyalto de Pablo, Silvia Comas, Cristina Carrato, Elena Valassi, and Manel Puig-Domingo. Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm. Endocrine, 89:20-29, May 2025. URL: https://doi.org/10.1007/s12020-025-04216-9, doi:10.1007/s12020-025-04216-9. This article has 3 citations and is from a peer-reviewed journal.

  16. (javidialsaadi2025advancesinthe pages 6-8): Mousa Javidialsaadi, Diego D. Luy, Heather L. Smith, Arba Cecia, Seunghyuk Daniel Yang, and Anand V. Germanwala. Advances in the management of craniopharyngioma: a narrative review of recent developments and clinical strategies. Journal of Clinical Medicine, 14:1101, Feb 2025. URL: https://doi.org/10.3390/jcm14041101, doi:10.3390/jcm14041101. This article has 7 citations.

  17. (wang2024multiomicsanalysisof pages 8-10): Xianlong Wang, Chuan Zhao, Jincheng Lin, Hongxing Liu, Qiuhong Zeng, Hua-Qing Chen, Ye Wang, Dapeng Xu, Wen Chen, Moping Xu, En Zhang, Da Lin, and Zhixiong Lin. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chinese Medical Journal, 137:859-870, Aug 2024. URL: https://doi.org/10.1097/cm9.0000000000002774, doi:10.1097/cm9.0000000000002774. This article has 21 citations and is from a peer-reviewed journal.

  18. (NCT05286788 chunk 1): MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma. Nationwide Children's Hospital. 2023. ClinicalTrials.gov Identifier: NCT05286788

  19. (ng2020anepidemiologyreport pages 8-9): Sam Ng, Sonia Zouaoui, Faiza Bessaoud, Valérie Rigau, Alexandre Roux, Amélie Darlix, Fabienne Bauchet, Hélène Mathieu-Daudé, Brigitte Trétarre, Dominique Figarella-Branger, Johan Pallud, Didier Frappaz, Thomas Roujeau, and Luc Bauchet. An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in france, 2008-2013. Neuro-oncology, 22:851-863, Dec 2020. URL: https://doi.org/10.1093/neuonc/noz227, doi:10.1093/neuonc/noz227. This article has 28 citations and is from a domain leading peer-reviewed journal.

  20. (NCT05525273 chunk 1): Eva Marie Erfurth, MD, PhD. Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma. Eva Marie Erfurth, MD, PhD. 2023. ClinicalTrials.gov Identifier: NCT05525273

  21. (cossu2024updateonneoadjuvant pages 1-2): Giulia Cossu, Daniele S. C. Ramsay, Roy T. Daniel, Ahmed El Cadhi, Luc Kerherve, Edouard Morlaix, Sayda A. Houidi, Clément Millot-Piccoli, Renan Chapon, Tuan Le Van, Catherine Cao, Walid Farah, Maxime Lleu, Olivier Baland, Jacques Beaurain, Jean Michel Petit, Brivaël Lemogne, Mahmoud Messerer, and Moncef Berhouma. Update on neoadjuvant and adjuvant braf inhibitors in papillary craniopharyngioma: a systematic review. Cancers, 16:3479, Oct 2024. URL: https://doi.org/10.3390/cancers16203479, doi:10.3390/cancers16203479. This article has 4 citations.

  22. (biswas2024practicalapplicationof pages 2-3): Chandrima Biswas, Guilherme Mansur, Kyle C. Wu, Daniel M. Prevedello, and Luma Ghalib. Practical application of precision oncology in adult onset craniopharyngiomas. Frontiers in Endocrinology, Nov 2024. URL: https://doi.org/10.3389/fendo.2024.1488958, doi:10.3389/fendo.2024.1488958. This article has 4 citations.

  23. (zhang2024brachytherapyincraniopharyngiomas pages 1-2): Li-Yuan Zhang, Wei Guo, Han-Ze Du, Hui Pan, Yun-Chuan Sun, Hui-Juan Zhu, Shuai-Hua Song, Xiao-Yuan Guo, Yue Jiang, and Qian-Qian Sun. Brachytherapy in craniopharyngiomas: a systematic review and meta-analysis of long-term follow-up. BMC Cancer, May 2024. URL: https://doi.org/10.1186/s12885-024-12397-1, doi:10.1186/s12885-024-12397-1. This article has 4 citations and is from a peer-reviewed journal.

  24. (apps2017geneticallyengineeredmouse pages 3-5): John Richard Apps and Juan Pedro Martinez‐Barbera. Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology. Brain Pathology, 27:364-369, Apr 2017. URL: https://doi.org/10.1111/bpa.12501, doi:10.1111/bpa.12501. This article has 17 citations and is from a domain leading peer-reviewed journal.

  25. (wang2024multiomicsanalysisof pages 3-5): Xianlong Wang, Chuan Zhao, Jincheng Lin, Hongxing Liu, Qiuhong Zeng, Hua-Qing Chen, Ye Wang, Dapeng Xu, Wen Chen, Moping Xu, En Zhang, Da Lin, and Zhixiong Lin. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chinese Medical Journal, 137:859-870, Aug 2024. URL: https://doi.org/10.1097/cm9.0000000000002774, doi:10.1097/cm9.0000000000002774. This article has 21 citations and is from a peer-reviewed journal.

  26. (NCT03224767 chunk 1): Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma. Alliance for Clinical Trials in Oncology. 2018. ClinicalTrials.gov Identifier: NCT03224767